Immunomonitoring Laboratory (IML)

LEADERSHIP: Kathleen Sheehan, PhD and Stephen Oh, MD, PhD

The Immunomonitoring Laboratory (IML) provides state-of-the-art analyses to monitor immunologic changes occurring during cancer immunotherapy and relate them to treatment outcomes. The IML both responds to investigator needs with customized analyses by highly trained staff and drives immunology-oncology data acquisition through the expansion of new technologies. The IML is led by Co-directors Stephen Oh, MD, PhD and Kathleen Sheehan, PhD, under the guidance of Robert D. Schreiber, Director of the Bursky Center for Human Immunology and Immunotherapy Programs.

LOCATION: 7th floor of the BJC Institute of Health, Washington University School of Medicine

PRICING: Please contact the core for current pricing of services offered.

TO ACCESS: Contact Yuko Morima
Email: [email protected]
Phone: (314) 273-7036

NIH PUBLIC ACCESS POLICY: As of April 7, 2008, the NIH requires investigators with a publication using Siteman (or other NIH-funded) shared resources to submit (or have submitted for them) their final, peer reviewed manuscripts to PubMed Central(PMC) upon acceptance of publication, to be made publicly available within 12 months of publication. Many journals automatically submit these for authors, but Washington University also has assistance available through the Becker Medical Library. Please see this resource for more information.

PUBLICATION ACKNOWLEDGEMENT: If research supported by the Immunomonitoring Laboratory results in publication, please acknowledge this support by including the following in your publication(s):

We thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, MO., for the use of the Immunomonitoring Laboratory, which provided __________ service. The Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant #P30 CA091842.